Astria Therapeutics Announces Closing of Underwritten Offering and Full Exercise of Underwriters’ Option to Purchase Additional Shares
20 December 2022 - 8:01AM
Business Wire
Astria Therapeutics, Inc. (“Astria Therapeutics,” “Astria,” the
“Company,” “our,” or “us”) (Nasdaq: ATXS), a biopharmaceutical
company developing STAR-0215 for the treatment of hereditary
angioedema and focused on life-changing therapies for rare and
niche allergic and immunological diseases, today announced the
closing of its previously announced underwritten offering of
10,445,050 shares of its common stock, including the full exercise
of the underwriters’ option to purchase 1,362,397 shares of common
stock, at a price of $11.01 per share. The gross proceeds of the
offering were approximately $115 million, before deducting
underwriting discounts and commissions and other offering expenses.
All shares in the offering were offered by the Company.
Jefferies and Evercore ISI acted as joint book-running managers
for the offering. LifeSci Capital and Oppenheimer & Co. acted
as co-lead managers and H.C. Wainwright & Co. acted as
co-manager for the offering.
The shares described above were offered pursuant to a shelf
registration statement on Form S-3 (File No. 333-264911), which was
declared effective by the Securities and Exchange Commission (the
“SEC”) on May 23, 2022. The offering was made only by means of a
prospectus supplement and the accompanying prospectus. A prospectus
supplement relating to the offering has been filed with the SEC and
is available at www.sec.gov. Copies of the prospectus supplement
and the accompanying prospectus may be obtained for free by
contacting Jefferies LLC, Attention: Equity Syndicate Prospectus
Department, 520 Madison Avenue, New York, NY 10022, by telephone at
(877) 821-7388, or by email at Prospectus_Department@Jefferies.com;
or Evercore Group L.L.C., Attention: Equity Capital Markets, 55
East 52nd Street, 35th Floor, New York, NY 10055, or by telephone
at (888) 474-0200, or by email at ecm.prospectus@evercore.com.
This press release does not constitute an offer to sell or the
solicitation of an offer to buy any of the shares described herein,
nor shall there be any sale of these shares in any jurisdiction in
which such offer, solicitation or sale would be unlawful prior to
the registration or qualification under the securities laws of any
such jurisdiction.
About Astria Therapeutics
Astria Therapeutics is a biopharmaceutical company, and our
mission is to bring life-changing therapies to patients and
families affected by rare and niche allergic and immunological
diseases. Our lead program, STAR-0215, is a monoclonal antibody
inhibitor of plasma kallikrein in clinical development for the
treatment of hereditary angioedema.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20221219005678/en/
Investor relations: Andrea Matthews
investors@astriatx.com
Media: Elizabeth Higgins media@astriatx.com
Astria Therapeutics (NASDAQ:ATXS)
Historical Stock Chart
From Mar 2024 to Apr 2024
Astria Therapeutics (NASDAQ:ATXS)
Historical Stock Chart
From Apr 2023 to Apr 2024